January 22, 2017 7:58 PM ET

Healthcare Equipment and Supplies

Company Overview of Beckman Coulter, Inc.

Company Overview

Beckman Coulter, Inc. develops, manufactures, and markets diagnostic systems for complex biomedical testing. The company’s research and discovery products and services include capillary electrophoresis, centrifugation, centrifugation, electrochemistry, flow cytometry, genetic analysis, genomic services, immunoassay, liquid handlers, library construction, nucleic acid sample preparation, particle characterization, research automation, single cell PCR, and spectrophotometers for use in cellular solutions, drug discovery and development, genetic analysis, genomic, protein analysis, and small molecule analysis. Its clinical products include automation, blood banking, centrifugation, chemistry, c...

250 South Kraemer Boulevard

Brea, CA 92821

United States

Founded in 1935

11,900 Employees





Key Executives for Beckman Coulter, Inc.

Chief Executive officer, President and Interim Diagnostic Division President
Age: 66
Chief Financial Officer and Senior Vice President
Age: 55
President of Europe Commercial Operations
Chief Scientific Officer and Senior Vice President of Molecular Diagnostics
Age: 63
Compensation as of Fiscal Year 2016.

Beckman Coulter, Inc. Key Developments

Beckman Coulter, Inc. and Ortho Clinical Diagnostics Announce Strategic Relationship to Deliver Infectious Disease Testing Menu to Very High-Volume Labs

Beckman Coulter, Inc. and Ortho Clinical Diagnostics announced a strategic relationship regarding sales of Ortho's VITROS® 3600 Immunodiagnostic System and infectious disease menu in the U.S. Ortho's VITROS® 3600 System offers a broad menu of infectious disease tests that are used by several of the leading reference laboratories in the United States. It combines three high-quality proprietary technologies into a single system that is self-monitoring, highly efficient and easy to use, enabling health care professionals to make better treatment decisions. Under this strategic relationship, Beckman Coulter will place Ortho's VITROS® 3600 System running HIV and hepatitis assays in labs that currently run Beckman's Power Processor Sample Handling Systems, and in certain other very high-volume laboratories. The arrangement will help very high-volume laboratories access infectious disease testing on the innovative VITROS® 3600 System, with market-leading automation systems. Together, the systems will help laboratories improve operational efficiency and enhance patient care. Beckman Coulter and Ortho will also collaborate to obtain clearance/approval from the U.S. Food and Drug Administration to connect the VITROS® 3600 System to the Power Processor to run infectious disease tests.

Beckman Coulter Launches New Cystatin C Assay

Beckman Coulter, Inc. has launched the new Cystatin C assay for its AU clinical low to ultra-high-volume family of chemistry systems and IMMAGE 800 immunochemistry systems. The Cystatin C assay on the Beckman Coulter AU clinical chemistry systems and IMMAGE 800 immunochemistry systems is an in vitro diagnostic test for quantitative determination of Cystatin C in human serum and plasma. The measurement of Cystatin C is used in the diagnosis and treatment of renal diseases. Cystatin C simplifies patient testing by not being as susceptible as other renal function tests to diet, gender, muscle mass, or age. The company's new Cystatin C assay will aid physicians in assessing kidney function and broaden the assay menu on the AU clinical chemistry platform. For added convenience, the assay is offered in a barcoded liquid ready use format for the AU and IMMAGE clinical chemistry systems. The Cystatin C assay has a proven track record on the Synchron DxC platforms, and the company to bring that best-in-class performance to both the AU and IMMAGE 800 systems." Features of the Cystatin C assay include: an all-liquid and ready-to-use reagent format; Particle enhanced turbidimetric immunoassay (PETIA); measuring range of 0.4 to 8.0 mg/L; total imprecision <10.0% CV; Monoclonal antibody; standardized against ERM-DA471/IFCC; and manufactured by Gentian AS. The Cystatin C based GFR (Glomerular Filtration Rate) calculation demonstrates correlation with the Creatinine based GFR calculation. The new assay's sensitivity is LOQ of 0.23mg/L, and assay range is 0.4 - 8.0 mg/L. On the AU systems, Cystatin C is an immunoturbidimetric method, and on the IMMAGE systems the method is a nephelometric method.

Beckman Coulter Wins Multiple Awardees Contract for Supplying Cell Counting Equipment

Beckman Coulter won a multiple awardees contract award from Centre for Process Innovation Ltd. for the supply of cell counting equipment. The lowest offer is GBP 51,579.20 and the highest offer is GBP 73,367.55.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Beckman Coulter, Inc., please visit www.beckmancoulter.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.